<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997201</url>
  </required_header>
  <id_info>
    <org_study_id>18SM4892</org_study_id>
    <nct_id>NCT03997201</nct_id>
  </id_info>
  <brief_title>Ripple Mapping Guided Ablation of Ischaemic Ventricular Tachycardia.</brief_title>
  <acronym>RIPPLE-VT</acronym>
  <official_title>Ripple Mapping Guided Ablation of Ischaemic Ventricular Tachycardia: A Multi-centre Prospective Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Santa Maria, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ripple VT-1 Study is a prospective clinical trial that aims to investigate if catheter&#xD;
      ablation of ventricular tachycardia in patients with ischaemic heart disease can be&#xD;
      effectively performed using Ripple Mapping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have ischaemic heart disease and are at sufficient risk of, or have suffered,&#xD;
      ventricular tachycardia may receive implantable cardioverter defibrillator (ICD) devices. ICD&#xD;
      devices provide life-saving shocks to terminate ventricular tachycardia. There is however&#xD;
      substantial evidence that correlates each life-saving shock with worsening prognosis.&#xD;
&#xD;
      Catheter ablation is a procedure that can treat the cause of ischaemic ventricular&#xD;
      tachycardia (VT). Most catheter ablation procedures for ischaemic VT are performed in normal&#xD;
      rhythm, with an end-point of arrhythmic substrate modification. Arrhythmic substrate&#xD;
      modification refers to the process by which abnormal electrical activity in cardiac scar&#xD;
      tissue (from ischaemic heart disease) is identified and treated by ablation.&#xD;
&#xD;
      Substrate modification catheter ablation procedures for ischaemic VT have been demonstrated&#xD;
      to reduce ICD shocks and VT episodes in randomised trials compared to medications. However,&#xD;
      ablation procedure outcomes are still imperfect with a recurrence rate of 50-60%.&#xD;
&#xD;
      Ripple Mapping is a method of mapping the hearts electrical signals, that may allow better&#xD;
      identification of the abnormal activity within scar and so improve recurrence rates following&#xD;
      ablation.&#xD;
&#xD;
      Patients referred for ablation of ischaemic VT, who have an ICD, will undergo their procedure&#xD;
      with Ripple Mapping and subsequently followed up over a year, at 3 monthly intervals. The&#xD;
      main assessed outcome will be ICD or VT events over a year. This will be compared to the&#xD;
      number of ICD or VT events the year prior to ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any appropriate ICD therapy</measure>
    <time_frame>12 months</time_frame>
    <description>ICD therapy (ATP and shocks) for sustained ventricular tachycardia or ventricular fibrillation as documented by the patients device. Device interrogations occur 3 monthly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of the ablation procedure protocol end-point</measure>
    <time_frame>Procedure</time_frame>
    <description>Abolition of abnormal electrical activity within ischaemic ventricular scar by Ripple Mapping guided ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ICD therapy rate</measure>
    <time_frame>12 months</time_frame>
    <description>Toral appropriate and inappropriate (defined as ICD therapies for reasons other than ventricular tachycardia/fibrillation) ICD therapies (ATP and shocks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat catheter ablation for ischaemic ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
    <description>Need for a repeat catheter ablation procedure after the study procedure and during the 12 month follow up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalisation</measure>
    <time_frame>12 months</time_frame>
    <description>All cause hospitalisation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Ripple Mapping guided ischaemic VT ablation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ripple Mapping guided ischaemic VT ablation</intervention_name>
    <description>Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal &quot;late&quot; electrical activity within ventricular scar tissue.</description>
    <arm_group_label>Ripple Mapping guided ischaemic VT ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with coronary artery disease and ischaemic cardiomyopathy requiring ICD&#xD;
             implantation for primary or secondary prevention.&#xD;
&#xD;
          2. Any episode of VT detected or treated appropriately (within monitor zone or therapy&#xD;
             (ATP/shock) delivered) or by 12 lead ECG if the rate below the detection level of the&#xD;
             device. An episode of VT will be defined as lasting more than 30 secs or a regular&#xD;
             high rate episode meeting VT criterion for &gt;50% of the time before the first therapy&#xD;
             is delivered (i.e. VT degenerating into VF is acceptable under these circumstances).&#xD;
&#xD;
          3. Ablation or medical therapy would be considered reasonable option for ongoing&#xD;
             management.&#xD;
&#xD;
          4. Males or females 18 - 80 years of age.&#xD;
&#xD;
          5. Suitable candidate for catheter ablation.&#xD;
&#xD;
          6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to catheter ablation.&#xD;
&#xD;
          2. VT due to reversible causes.&#xD;
&#xD;
          3. Severe valvular disease or ventricular thrombus.&#xD;
&#xD;
          4. Active gastrointestinal bleeding.&#xD;
&#xD;
          5. Serum Creatinine &gt;200Î¼mol/L or on dialysis.&#xD;
&#xD;
          6. Active fever or infection.&#xD;
&#xD;
          7. Life expectancy shorter than the duration of the trial.&#xD;
&#xD;
          8. Allergy to contrast.&#xD;
&#xD;
          9. Intractable heart failure (NYHA Class IV).&#xD;
&#xD;
         10. Bleeding or clotting disorders or inability to receive heparin.&#xD;
&#xD;
         11. Malignancy needing surgery, chemotherapy or radiotherapy.&#xD;
&#xD;
         12. Pregnancy or women of child-bearing potential not using a highly effective method of&#xD;
             contraception.&#xD;
&#xD;
         13. Unable to attend follow-up visits or ICD clinics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prapa Kanagaratnam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Katritsis, MBChB</last_name>
    <phone>020 3313 1000</phone>
    <email>g.katritsis@ic.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prapa Kanagaratnam, MD, PhD</last_name>
    <phone>020 3313 1000</phone>
    <email>p.kanagaratnam@ic.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hammersmith Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Katritsis, MBChB</last_name>
      <email>g.katritsis@ic.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Prapa Kanagaratnam, MD, PhD</last_name>
      <email>p.kanagaratnam@ic.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>Ischaemic</keyword>
  <keyword>Mapping</keyword>
  <keyword>Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

